As Merck received its latest FDA nod for Keytruda in ovarian cancer, Agilent gained the green light for its accompany...
Merck's Keytruda received FDA approval for ovarian cancer and Agilent earned FDA clearance for a companion diagnostic to identify patients likely to benefit.
Why it mattersFDA clearance for Agilent's companion diagnostic for Keytruda in ovarian cancer allows hospitals to prioritize patients for immunotherapy.